Palatin Reports Fiscal First Quarter 2027 Financial Results and Provides Business Update
PR Newswire•17/11/2026•07:30 ET
0
Key Highlights
- ➤Cash $3.7M; company says additional financing is required and substantial doubt exists regarding going concern
- ➤Revenue $0.4M versus $8.8M year over year as prior period included upfront and milestone revenue
- ➤Net loss $5.1M, or $1.29 per share, versus prior-year net income of $4.7M
- ➤Lead long-acting peptide Phase 1 targeted for first half of calendar 2027, with initial data targeted second half
- ➤MC4R obesity R&D spending $2.1M, more than doubled from approximately $1.0M prior year
Expert Statements
Carl Spana, President and Chief Executive Officer of Palatin Technologies
“MC4R agonism is now a clinically and commercially validated therapeutic approach for rare neuroendocrine obesity disorders, and we believe the next generation of therapies will be defined not only by efficacy, but by meaningful improvements in tolerability, convenience and long-term usability.”
Carl Spana, President and Chief Executive Officer of Palatin Technologies
“Our development strategy is specifically designed to address these challenges. We are building on more than two decades of melanocortin research and drug development experience to advance highly selective MC4R agonists with the potential to deliver robust efficacy while substantially reducing, and potentially eliminating, MC1R-mediated hyperpigmentation.”
Carl Spana, President and Chief Executive Officer of Palatin Technologies
“Our lead lipidated peptide program represents a particularly compelling opportunity”
Carl Spana, President and Chief Executive Officer of Palatin Technologies
“We have demonstrated significant efficacy with once-weekly dosing in preclinical models, and pharmacokinetic findings support the potential for once-weekly or less frequent administration in humans. Equally important, tested compounds in our next-generation peptide series have demonstrated potent MC4R activation without meaningful MC1R activation, an important attribute for developing therapies with improved long-term tolerability. We believe this combination of selectivity, efficacy and sustained activity provides a strong foundation for developing a differentiated therapy for patients who require lifelong treatment.”
Carl Spana, President and Chief Executive Officer of Palatin Technologies
“During the quarter, we continued to advance IND-enabling activities with our long-acting peptide while progressing our next-generation oral small-molecule candidates and additionally exploring oral peptide opportunities. We are targeting the initiation of our first Phase 1 study in the first half of 2027, followed by our oral small-molecule program in the second half of 2027. We believe these programs have the potential to establish a new standard for MC4R-targeted treatment of rare obesity disorders.”
Palatin Reports Fiscal First Quarter 2027 Financial Results and Provides Business Update PR Newswire
Advancing differentiated next-generation MC4R agonists toward first-in-human clinical studies in 2027
Get started
Create a free account to read the full story.
